Manifest Technologies is a Yale University spinout founded in 2021, developing the NAIO™ platform, an AI-powered computational neuroimaging system for Central Nervous System (CNS) drug research and development.[1][2] The platform automates the integration, processing, and analysis of large multimodal neuroimaging datasets from humans and animals, enabling precision neural target selection, patient stratification, and clinical trial enrichment to de-risk CNS therapies.[1][2] It serves pharmaceutical companies and healthcare providers tackling challenges in psychiatry and neurology, such as validating drug mechanisms, discovering novel targets, and personalizing treatments, building on over $50M in prior NIH funding to the founders' labs.[1][2]
The company addresses high failure rates in CNS drug R&D by mapping animal data to human brain circuitry for early go/no-go decisions and optimizing neurobehavioral assessments via proprietary machine learning.[1][2] Recent momentum includes emerging from stealth with strategic investors, co-authored papers in PLOS Biology and JAMA Psychiatry on brain activity patterns and mental disorder heterogeneity, and YaleNews coverage of their ketamine response and psychiatric personalization tools.[2]
Manifest Technologies originated as a Yale School of Medicine spinout in 2021, founded by leading experts in computational neuroimaging and psychiatry whose labs received over $50M in NIH funding.[1][2] The idea emerged from their research integrating human and animal neuro data to accelerate CNS drug discovery, addressing longstanding inefficiencies in translating preclinical findings to human trials.[1]
Early traction built through validated scientific publications, including PLOS Biology findings on shared brain activity patterns across hundreds of individuals and JAMA Psychiatry work quantifying symptom heterogeneity in mental disorders.[2] Pivotal moments include YaleNews highlights on ketamine's brain responses and a Yale-developed tool for personalized psychiatric care, culminating in a Business Wire announcement of exiting stealth mode with investors to advance the NAIO™ platform.[2]
(Note: References to "MANIFEST Technology," an unrelated Minnesota-based IT consulting firm, do not apply here.[3][4][6])
Manifest Technologies rides the AI-neuroscience convergence trend, applying machine learning to multimodal brain data amid rising demand for precision medicine in CNS disorders, where 90%+ of drugs fail due to translation gaps.[1] Timing aligns with explosive growth in neuroimaging datasets, post-COVID mental health crises, and pharma's push for biomarkers—enabling faster, cheaper R&D phases.[2]
Market forces like NIH funding for AI-health tools and Big Pharma's $100B+ annual CNS spend favor scalable platforms like NAIO™, reducing trial costs by 20-30% via stratification.[1] The company influences the ecosystem by open-sourcing insights through Yale collaborations, fostering academic-pharma bridges and accelerating individualized brain therapeutics.[2]
Manifest Technologies is poised to scale NAIO™ applications for pharma pipelines and clinical use, targeting partnerships with CNS giants amid AI biomarker booms.[2] Trends like federated learning for privacy-protected neurodata and multimodal AI (e.g., integrating genomics) will amplify their edge, potentially capturing share in the $50B+ neuroimaging market.[1]
Influence may evolve toward therapeutic co-development or health provider tools, de-risking a sector ripe for disruption—echoing their origin as a Yale powerhouse now primed for global CNS impact.[1][2]
Manifest has raised $4.0M in total across 2 funding rounds.
Manifest's investors include Circle Ventures, MATR Ventures, D’Arcy Coolican, Shayne Coplan, Stefan George, Felicis Ventures, Greycroft, IVP, Pelion Venture Partners, Raine Ventures, Shasta Ventures, The Hit Forge.
Manifest has raised $4.0M across 2 funding rounds. Most recently, it raised $3.0M Seed in March 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2025 | $3.0M Seed | Circle Ventures, MATR Ventures, D’Arcy Coolican, Shayne Coplan, Stefan George | |
| May 1, 2013 | $1.0M Seed | Felicis Ventures, Greycroft, IVP, Pelion Venture Partners, Raine Ventures, Shasta Ventures, The Hit Forge, Uncork Capital, Steve Krausz, Sean Flynn, Tom McInerney |
